October 29, 2019
A $750 million settlement this week by Allergan to avert an antitrust trial involving Alzheimer's drug Namenda is among the most eye-popping sums ever shelled out by a drugmaker for allegedly thwarting generic competition.
February 25, 2019
A Connecticut federal judge on Monday refused the Orange County District Attorney's request to dismiss a $54 million settlement between indirect purchasers of stroke prevention medicine and Teva Pharmaceutical and Boehringer Ingelheim in antitrust multidistrict litigation, saying the county did not show the court lacked jurisdiction over the parties.
July 20, 2018
A Connecticut federal judge has signed off on a $54 million settlement between indirect purchasers of stroke prevention medicine Aggrenox and drugmakers Teva Pharmaceutical and Boehringer Ingelheim to end allegations the companies blocked generic alternatives to the drug from coming to the market.
June 14, 2018
Indirect buyers of the stroke prevention medicine Aggrenox on Wednesday slammed a request by six insurance companies to opt out hundreds of potential class members from a $54 million settlement agreement over an alleged pay-for-delay scheme, saying the companies have failed to show they are authorized to make such a request.
June 11, 2018
Teva Pharmaceutical and Boehringer Ingelheim on Monday announced a settlement with the last remaining party accusing them of entering into an illegal pay-for-delay agreement to keep a generic version of the stroke prevention medicine Aggrenox off the market, paving the way for the multidistrict litigation in Connecticut federal court to close out.
June 04, 2018
Insurer Humana Inc. told a Connecticut federal court Friday it reached a confidential settlement with Teva Pharmaceutical and Boehringer Ingelheim, so its claims that the drugmakers blocked generic alternatives to the stroke-prevention drug Aggrenox from coming to the market could be tossed.
April 13, 2018
Indirect buyers of Aggrenox told a Connecticut federal judge Friday that attorneys who represented the putative class alleging that Teva Pharmaceutical and Boehringer Ingelheim blocked generic alternatives to the stroke-prevention drug from coming to the market should get $18 million of the proposed $54 million settlement.
March 20, 2018
Blue Cross and Blue Shield of Louisiana on Monday urged a Connecticut federal judge to nix a sanctions bid from Boehringer Ingelheim and Teva in multidistrict litigation over an alleged pay-for-delay scheme for a generic of Aggrenox, saying the motion has "lost urgency and importance" as a result of recent schedule changes.
February 28, 2018
Boehringer Ingelheim and Teva have asked a Connecticut federal court to sanction Blue Cross and Blue Shield of Louisiana for allegedly dodging discovery in multidistrict litigation in which it's accusing the drugmakers of entering into a $120 million pay-for-delay deal aimed at blocking generic versions of the stroke-prevention medication Aggrenox.
February 06, 2018
Boehringer Ingelheim and Teva Pharmaceutical urged a Connecticut federal judge Monday to ignore objections raised by Humana to a $54 million settlement reached with a proposed class of indirect Aggrenox buyers over allegations the drug companies blocked generic alternatives to the stroke-prevention medication from hitting the market.